Hall Capital Management Co. Inc. Has $669,000 Position in Thermo Fisher Scientific Inc (TMO)

Hall Capital Management Co. Inc. reduced its holdings in Thermo Fisher Scientific Inc (NYSE:TMO) by 0.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,833 shares of the medical research company’s stock after selling 25 shares during the period. Hall Capital Management Co. Inc.’s holdings in Thermo Fisher Scientific were worth $669,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Proficio Capital Partners LLC lifted its holdings in Thermo Fisher Scientific by 71.5% in the first quarter. Proficio Capital Partners LLC now owns 607 shares of the medical research company’s stock valued at $105,000 after buying an additional 253 shares during the period. Cribstone Capital Management LLC lifted its holdings in Thermo Fisher Scientific by 8.7% in the second quarter. Cribstone Capital Management LLC now owns 625 shares of the medical research company’s stock valued at $109,000 after buying an additional 50 shares during the period. Shine Investment Advisory Services Inc. acquired a new position in Thermo Fisher Scientific in the second quarter valued at approximately $113,000. Chicago Partners Investment Group LLC acquired a new position in Thermo Fisher Scientific in the second quarter valued at approximately $108,000. Finally, CWM LLC lifted its holdings in Thermo Fisher Scientific by 17.0% in the second quarter. CWM LLC now owns 710 shares of the medical research company’s stock valued at $124,000 after buying an additional 103 shares during the period. Institutional investors and hedge funds own 83.61% of the company’s stock.

In other Thermo Fisher Scientific news, VP Seth H. Hoogasian sold 4,140 shares of the company’s stock in a transaction on Monday, August 28th. The shares were sold at an average price of $177.80, for a total transaction of $736,092.00. Following the transaction, the vice president now owns 25,518 shares in the company, valued at $4,537,100.40. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Jim P. Manzi sold 1,000 shares of the company’s stock in a transaction on Thursday, August 17th. The stock was sold at an average price of $175.20, for a total transaction of $175,200.00. Following the transaction, the director now owns 38,757 shares in the company, valued at approximately $6,790,226.40. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 22,738 shares of company stock worth $4,021,512. Corporate insiders own 0.49% of the company’s stock.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.31 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The firm had revenue of $5.12 billion for the quarter, compared to the consensus estimate of $5.03 billion. During the same quarter in the prior year, the company posted $2.03 earnings per share. The business’s revenue was up 13.9% on a year-over-year basis.

Several equities analysts recently weighed in on TMO shares. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $208.00 price objective on the stock in a report on Thursday, September 7th. Morgan Stanley restated an “overweight” rating and issued a $220.00 price objective on shares of Thermo Fisher Scientific in a report on Wednesday, September 6th. Cowen and Company restated an “outperform” rating and issued a $220.00 price objective (up from $200.00) on shares of Thermo Fisher Scientific in a report on Sunday, September 10th. Cleveland Research upgraded shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a report on Thursday, July 20th. Finally, Bank of America Corporation restated a “buy” rating and issued a $210.00 price objective (up from $200.00) on shares of Thermo Fisher Scientific in a report on Friday, July 21st. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $205.71.

TRADEMARK VIOLATION WARNING: “Hall Capital Management Co. Inc. Has $669,000 Position in Thermo Fisher Scientific Inc (TMO)” was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://sportsperspectives.com/2017/11/02/hall-capital-management-co-inc-has-669000-position-in-thermo-fisher-scientific-inc-tmo.html.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply